Hematologic Oncology | Specialty

Safety and Efficacy of Elotuzumab in Multiple Myeloma

March 29th 2016

Safety and Efficacy of Daratumumab in Multiple Myeloma

March 29th 2016

Monoclonal Antibody Therapy in Myeloma

March 29th 2016

Rationale for Immunotherapy in Multiple Myeloma

March 29th 2016

The C Letter Word

March 28th 2016

Hematology/oncology fellowship coordinator, Theresa Marcus, reflects on what it was like to receive a diagnosis of cancer, experience recurrence, and later learn that she had finally become cancer-free with the help of her colleagues.

Does Physician-Physician Communication Matter?

March 28th 2016

Faisal Musa, MD, reviews the case of a patient with large granulocytic leukemia and discusses why collaborating with the patient’s pathologist was so important to her diagnosis.

CAR T-cells Rapidly Evolving as Cancer Therapies

March 20th 2016

Chimeric antigen receptor-modified T-cell therapies have demonstrated durable complete responses for patients with relapsed/refractory B-cell acute lymphoblastic leukemia; however, several questions remain regarding their optimal use and applicability outside of this disease.

Potential of Immuno-Oncology Continues to Expand

March 19th 2016

Immuno-oncology has advanced rapidly, with the introduction of immune checkpoint inhibition and effective adoptive T-cell therapies. As these agents rush through development, several questions remain regarding the optimal patients for treatment and the next steps for further improving outcomes.

Kareem Abdul-Jabbar Discusses Living With CML

March 18th 2016

Kareem Abdul-Jabbar, retired NBA player for the Milwaukee Bucks and the Los Angeles Lakers, discusses his experience with chronic myeloid leukemia‎ (CML) at the 20th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma, held March 18.

CPX-351 Improves OS in Phase III AML Study

March 15th 2016

Frontline treatment with CPX-351 (Vyxeos) significantly reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary acute myeloid leukemia.

Progress and Promise in the Treatment of MDS

March 8th 2016

MDS: The Current Understanding in Molecular Testing and Biomarkers

March 8th 2016

The Future Role of Blood Transfusions in MDS

March 8th 2016

When a High-Risk Patient with MDS Might Be Low-Risk

March 8th 2016

Factors to Consider in Iron Chelation Therapy

March 8th 2016

Iron Chelation Therapy in MDS: A Look at the Evidence

March 8th 2016

Iron Chelation Therapy Efficacy and Safety in MDS

March 8th 2016

MDS and Iron Overload: An Argument for Iron Chelation Therapy

March 8th 2016

Appropriate Use of Iron Chelators in MDS

March 8th 2016

The Role of Iron Chelation Therapy in Patients with MDS

March 8th 2016